Left Menu
Development News Edition

U.S. allows emergency use of Eli Lilly's COVID-19 antibody therapy

Results from a study of 452 patients with mild-to-moderate COVID-19 published in a peer-reviewed journal in late October found that 1.6% of those who got the antibody infusion had to be hospitalized or required an emergency room visit, compared with 6.3% of those who received a placebo. The company has said it plans to pursue a similar authorization in November for its two-antibody cocktail, which it described as having helped reduce viral levels even more than the single-antibody treatment.

Reuters | Updated: 10-11-2020 05:50 IST | Created: 10-11-2020 05:50 IST
U.S. allows emergency use of Eli Lilly's COVID-19 antibody therapy

The U.S. Food and Drug Administration on Monday authorized emergency use of Eli Lilly and Co's experimental COVID-19 antibody treatment for non-hospitalized patients older than 65 or who have certain chronic medical conditions. The FDA said its emergency use authorization (EUA) was based on clinical trials showing that the treatment, bamlanivimab, reduced the need for hospitalization or emergency room visits in COVID-19 patients at high risk of disease progression.

It can now be used for treating mild-to-moderate COVID-19 in adults and pediatric patients over the age of 12, the FDA said. The antibody is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. The FDA said the drug, which U.S. President Donald Trump has praised, had not been shown to benefit such patients and could worsen their clinical status.

A U.S. government-sponsored study of the treatment in hospitalized COVID-19 patients was recently abandoned because the treatment was not shown to be helping. In early October, Eli Lilly requested EUA for its single-antibody therapy. Results from a study of 452 patients with mild-to-moderate COVID-19 published in a peer-reviewed journal in late October found that 1.6% of those who got the antibody infusion had to be hospitalized or required an emergency room visit, compared with 6.3% of those who received a placebo.

The company has said it plans to pursue a similar authorization in November for its two-antibody cocktail, which it described as having helped reduce viral levels even more than the single-antibody treatment. Both treatments are monoclonal antibodies – a widely used class of biotech drugs that are manufactured copies of antibodies created by the human body to fight infections.

Lilly expects to supply as many as one million doses of the single-antibody therapy in the fourth quarter, with 100,000 doses available in October. It struck a $1,250 per dose deal with the U.S. government and plans to sell to other countries. Shares of the Indianapolis drugmaker, which closed little changed at $142.33 in regular trading, were up 3.6% after hours.

Several other drugmakers, including Regeneron Pharmaceuticals Inc, are testing antibody treatments for COVID-19. Regeneron's antibody treatment was given to Trump after he caught the virus in early October. The nation's top infectious disease expert Dr. Anthony Fauci said it likely contributed to his recovery.

(Additional reporting by Vishwadha Chander in Bengaluru; Editing by Tom Brown and Stephen Coates)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

China: A savior for emerging markets or a poison pill?

... ...

Future of Urban Planning: Artificial Intelligence guiding the way

Advances in emerging technologies like Artificial Intelligence and Machine Learning can help us understand our cities better and derive useful insights from real-time data collected through automated models....

Videos

Latest News

3 dead in military helicopter crash were experienced pilots

The three National Guard members killed when a helicopter crashed in an upstate New York field this week were experienced pilots with past deployments to Afghanistan, officials said Friday.Killed in the crash were Chief Warrant Officer 5 St...

Soccer-Leicester's Vardy to have hernia operation, says Rodgers

Leicester Citys in-form striker Jamie Vardy will be sidelined for a few weeks to have a hernia operation, manager Brendan Rodgers said on Friday.Vardy, 34, has scored 11 Premier League goals this season and is in the running for the golden ...

Italian risk premium highest since November as focus shifts to elections

Italian bond yields rose again on Friday as focus turned back to political uncertainty in Rome, a day after yields jumped when the European Central Bank was perceived as more hawkish than expected at its policy meeting.Italys main ruling pa...

NTPC to raise Rs 2,500 cr via bonds on Wednesday

State-owned power giant NTPC on Friday said it will raise Rs 2,500 crore through issuance of non-convertible bonds via private placement on January 27.NTPC has decided to issue unsecured non-convertible bonds in the nature of debentures of ...

Give Feedback